Sanofi gets nod for new polio vaccine in India

Drug agency Sanofi on Friday stated it has obtained approval for IMOVAX-Polio, an alternate injectable vaccine, to exchange the Inactivated Polio Vaccine (IPV) ShanIP in India. IMOVAX-Polio is an alternate IPV vaccine that has been utilized in greater than 100 international locations for over 40 years, a Sanofi India spokesperson informed PTI.

The vaccine has the identical composition/formulation as ShanIPV, the spokesperson added.

“We want to guarantee all stakeholders that there will probably be no scarcity of IPV vaccines in India on our account, in direction of safeguarding the nation’s standing of remaining polio-free. We stay totally dedicated to fulfilling our public well being mission in India,” the spokesperson famous.

To make sure that there isn’t a interruption to the supply of IPV vaccines, the French agency has already obtained approvals for IMOVAX-Polio.

“…Sanofi has needed to adapt its technique and portfolio to those (rising) tendencies. Accordingly, Sanofi Healthcare India Pvt Ltd (SHIPL) introduced that by the tip of 2023, it should discontinue ShanIPV, which was solely stuffed and packaged at our manufacturing unit in Hyderabad, India,” the spokesperson added.

Launched in India in 2015, ShanIPV is a trivalent inactivated injectable vaccine. Underneath the federal government’s immunisation programme, the vaccine was injected in two phases – at six weeks and 14 weeks of age. Sanofi and Serum Institute of India are the main suppliers of IPV vaccines in India.